Five-year evaluation of bloodstream yeast infections in a tertiary hospital: The predominance of non-C. albicans Candida species

Medical Mycology

Volumn 48, Issue 6, 2010, Pages 839-842

  Pereira, Graziella H ^a   Müller, Patrcia Rady ^a   Szeszs, Maria Walderez ^b   Levin, Anna S ^c   Melhem, Mrcia S C ^b  

^a HOSPITAL BRIGADEIRO   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bloodstream yeast infections; Fungemia; Non C. albicans Candida species

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDA ZEYLANOIDES; CANDIDEMIA; CENTRAL VENOUS CATHETER; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUNGEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; INTENSIVE CARE UNIT; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOSIS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RHODOTORULA; SCHOOL CHILD; SOLID TUMOR; TERTIARY HEALTH CARE; TRICHOSPORON ASAHII;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; FEMALE; FUNGEMIA; HOSPITALS; HUMANS; INFANT; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; RHODOTORULA; TRICHOSPORON; YOUNG ADULT;

CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDA ZEYLANOIDES; TRICHOSPORON ASAHII;

EID: 77955883075     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903580121     Document Type: Article

References (25)

1. Colombo AL, Guimaraes T, Silva LR, et al. Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 2007; 28: 570-576.
2. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
3. Costa SF, Marino I, Araujo EA, et al. Nosocomial fungaemia: a 2-year prospective study. J Hosp Infect 2000; 45: 69-72.
4. Godoy P, Tiraboschi IN, Severo LC, et al. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz 2003; 98: 401-405.
5. Medrano DJ, Brilhante RS, Cordeiro R de A, et al. Candidemia in a Brazilian hospital: the importance of Candida parapsilosis. Rev Inst Med Trop Sao Paulo 2006; 48: 17-20.
6. Giusiano G, Mangiaterra M, Saito VG, et al. Etiology of fungaemia and catheter colonization in Argentinean paediatric patients. Mycoses 2006; 49: 49-54.
7. Matta VLR, Melhem MSC, Colombo AL, et al. Susceptibility profile to antifungal drugs of Pichia anomala isolated from patients presenting nosocomial fungemia. Antimicrob Agents Chemother 2007; 51: 1573-1576.
8. Pfaller MA, Messer SA; Hollis R, et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999; 33: 217-222.
9. Da Matta DA, Machado AM, Azevedo AC, et al. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Sao Paulo, Brazil, 1995- 2003. Diagn Microbiol Infect Dis 2007; 57: 399-404.
10. Cuenca-Estrella M, Rodriguez-Tudela JL. Red regional de laboratorios para la vigilancia de las infecciones fungicas invasoras y susceptibilidad a los antifungicos. Pan Amer J Pub Heal 2008; 23: 129-134.
11. EUCAST-The European Committee on Antimicrobial Susceptibility Testing. [Updated 16 April 2009]. Available from: .
12. Dannaoui E, Paugam A, Develoux M, et al. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories Clin Microbiol Infect 2009; Sep 23. [Epub ahead of print].
13. Pasqualotto AC, Nedel WL, Machado TS, Severo L. A 9-year study comparing risk factors and the outcome of paediatric and adults with nosocomial candidaemia. Mycopathologia 2005; 160: 111-116. (Pubitemid 41361230)
14. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
15. Gomez-Lopez A, Pan D, Cuesta I, et al. Molecular identification and susceptibility profile in vitro of the emerging pathogen Candida kefyr. Diagn Microbiol Infect Dis 2010; 66:116-119.
16. Milici ME, Maida CM, Spreghini E, et al. Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. J Clin Microbiol 2007; 45: 3529-3533.
17. Playford EG, Marriott D, Nguyen Q, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non- albicans Candida spp. Crit Care Med 2008; 7: 2034-2039.
18. Bassetti M, Trecarichi EM, Righi E, et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 3: 325-331.
19. Brito LR, Guimaraes T, Nucci M, et al. Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med Mycol 2006; 44: 261-266.
20. Miranda LN, van der Heijden IM, Costa SF, et al. Candida colonisation as a source for candidaemia. J Hosp Infect 2009; 72: 9-16.
21. Tay ST, Na SL, Chong J. Molecular differentiation and antifungal susceptibilities of Candida parapsilosis isolated from patients with bloodstream infections. J Med Microbiol 2009; 58: 185-191.
22. Lin D, Wu LC, Rinaldi MG, et al. Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol 1995; 33: 1815-1821.
23. Tavanti A, Davidson AD, Gow NA, et al. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-292.
24. van Asbeck E, Clemons KV, Martinez M, et al. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008; 62: 106-109.
25. Goldani LZ, Mario PS. Candida tropicalis fungemia in a tertiary care hospital. J Infect 2003; 46: 155-160.